Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Christophe Le Tourneau, MD, PhD
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Paolo A. Ascierto, MD
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Stephen Liu, MD
Joshua K. Sabari, MD
Susan Scott, MD
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Hussein Tawbi, MD, PhD
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
MET and Other Emerging Targets in Metastatic NSCLC
Applications of Emerging Data in Resectable NSCLC
Strategies in EGFR-mutated Unresectable Stage III NSCLC
Reimagining Lung Cancer Treatment: A Journey Through New and Emerging Therapeutics Related to the Care of Patients with Small Cell and Non-Small Cell Lung Cancer
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Eileen O’Reilly, MD
Efrat Dotan, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.